+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815



Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815



European Journal of Cancer and Clinical Oncology 19(11): 1529-1537



A previous report from this laboratory demonstrated that treatment of mouse mastocytoma P815 with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) produces tumor cell variants that are unable to form tumors in syngeneic animals. We examined whether repeated mutagen treatment could increase the frequency of tum- variants above that obtained after a single treatment. This was found to occur with frequencies increasing from a few percent after 1 treatment to more than 90% after 8 treatments. Moreover, uncloned survivor populations obtained after 8 or more MNNG cycles that contained such a high proportion of tum- variants had a markedly decreased tumorigenicity for syngeneic mice. As reported for tum- variants obtained after 1 mutagen treatment, several tum- variants obtained after repeated treatments carried new variant-specific antigens that elicited a specific cytolytic T cell response. Some of these tum- antigens were found to consist of multiple determinants that could be lost independently. We observed that the resistance of the mutagenized populations to MNNG increased gradually with the number of mutagen treatments. In addition, some tum- variants obtained after 8 mutagen treatments showed a reduced sensitivity to mitomycin C.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 043375339

Download citation: RISBibTeXText

PMID: 6196202

DOI: 10.1016/0277-5379(83)90082-2


Related references

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. Journal of Experimental Medicine 152(5): 1175-1183, 1980

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Ii. T lymphocyte-mediated cytolysis. Journal of Experimental Medicine 152(5): 1184-1193, 1980

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. European Journal of Immunology 12(11): 905-908, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. European Journal of Immunology 12(5): 406-412, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. European Journal of Immunology 12(5): 401-406, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9(3): 345-357, 1983

Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics 26(3): 178-187, 1987

Tum variants: immunogenic variants obtained by mutagen treatment of tumor cells. Immunology Today 6(10): 307-311, 1985

The induction of enhanced antitumor effect against a nonimmunogenic tumor by highly immunogenic variants obtained by mutagen treatment. Japanese Journal of Cancer Research 79(11): 1247-1254, 1988

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. Journal of Experimental Medicine 157(3): 1040-1052, 1983

Increased expression of class I MHC molecules on immunogenic cells derived from the xenogenization of P815 mastocytoma cells with 8-methoxypsoralen and long-wavelength ultraviolet radiation. Journal of Investigative Dermatology 104(4): 645, 1995

Increased surface expression of class I MHC molecules on immunogenic cells derived from the xenogenization of P815 mastocytoma cells with 8-methoxypsoralen and long-wavelength ultraviolet radiation. Tissue Antigens. 46(1): 45-49, 1995

Tumour cell variants with increased immunogenicity obtained by mutagen treatment. Cancer Surveys 4(1): 135-148, 1985

Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Research 43(1): 125-132, 1983

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proceedings of the National Academy of Sciences of the United States of America 85(7): 2274-2278, 1988